Prostate-specific membrane antigen (PSMA) is expressed in normal human prostate epithelium and is highly up-regulated in prostate cancer.
Introduction
Prostate cancer is the most commonly diagnosed malignancy and the second leading cause of cancer-related deaths in men in the United States (1) . In 2009, it is estimated that 192,000 men will be diagnosed with prostate cancer and 27,000 men will die of the disease (1) . Current diagnosis is typically through digital rectal exam and blood prostate-specific antigen (PSA) testing. Since the introduction of serum PSA screening, prostate cancer incidence rates have increased dramatically as have the number of men being treated for the disease (2) . However, 20% to 30% of men with prostate cancer have serum PSA levels within the reference range, resulting in false negatives (3, 4) , whereas others have elevated serum PSA levels due to conditions other than prostate cancer (i.e., benign prostatic hyperplasia), resulting in false positives and unnecessary biopsies (5) . Because elevated serum PSA levels do not always correlate with disease, there is skepticism regarding the value of broad-based PSA testing with regard to predicting surgical cures (6) . Initial results from the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial showed that annual PSA testing for 6 years and annual digital rectal exam testing for 4 years (performed in the same years as the first four PSA tests) did not reduce the number of deaths from prostate cancer through a median follow-up period of 11.5 years. These results suggest that many men were diagnosed with, and treated for, cancers that would not have been detected in their lifetime without screening and, as a consequence, were exposed to the potential harms of unnecessary treatments, such as surgery and radiation therapy (7) . Therefore, accurate initial diagnosis and determination of the extent of disease continues to be a major challenge for selecting appropriate treatment options, monitoring the effects of therapeutic interventions, and detecting disease after recurrence. New agents that will more accurately diagnose and stage prostate cancer, as well as monitor therapy, will enable improved treatment planning and result in improved patient outcome.
Prostate-specific membrane antigen (PSMA), also known as folate hydrolase I or glutamate carboxypeptidase II, is a transmembrane, 750 amino acid, type II glycoprotein that is primarily expressed in normal human prostate epithelium but is overexpressed in prostate cancer, including metastatic disease (8) (9) (10) . PSMA is an Nacetylated-a-linked acidic dipeptidase (NAALADase) with reactivity toward poly-g-glutamyl folates and has the capability of sequentially removing the poly-g-glutamyl termini of dipeptides (11, 12) . Because PSMA is expressed by virtually all prostate cancers and its expression is further increased in poorly differentiated, metastatic and hormone-refractory carcinomas (9) , it is a very attractive target for prostate cancer imaging and therapy.
PSMA was originally identified as the ligand of the monoclonal antibody 7E11-C5, marketed as ProstaScint (Capromab Pendetide), with a histologic profile that showed a high degree of specificity for the LNCaP human adenocarcinoma cell line (10) . ProstaScint is not in widespread use in part because it targets the intracellular domain of PSMA (amino terminus) and is believed to bind mostly necrotic portions of prostate tumors and not to viable tumor cells (13, 14) . More recently, radiolabeled monoclonal antibodies that bind to the extracellular domain of PSMA have been developed and have been shown to accumulate in PSMA-positive prostate tumor models in animals (15) . Early promising results from clinical trials have shown the utility of PSMA as a diagnostic and therapeutic target (16, 17) . Although monoclonal antibodies hold promise for tumor detection and therapy, there have been limited clinical successes outside of lymphoma because of their long circulating plasma half-lives and low permeability in solid tumors, particularly in metastases to the bone. Lower molecular weight small molecules, with higher permeability in solid tumors, will likely have an advantage. In addition, small molecules will likely display improved pharmacokinetics in normal tissues compared with intact immunoglobulins, making lesion detection more conspicuous.
Recently, Maresca and colleagues (18) 
Materials and Methods
Synthesis and radiolabeling of MIP-1072 and MIP-1095. The synthesis of MIP-1072 (S)-2-(3-((S)-1-carboxy-5-(4-iodobenzylamino)pentyl) ureido)pentanedioic acid and MIP-1095 (S )-2-(3-((S )-1-carboxy-5-(3-(4-iodophenyl)ureido)pentyl)ureido)pentanedioic acid, along with the radiolabeling precursors trimethyltin-MIP-1072 and trimethyltin-MIP-1095, and their subsequent radiolabeling with 123 I were described previously (18) . Briefly, radiolabeling was accomplished by iododestannylation of the trimethylstannyl precursors (S)-di-tert-butyl 2-(3-((S)-1-tert-butoxy-1-oxo-6-(4-(trimethylstannyl)benzylamino)hexan-2-yl)ureido)pentanedioate and (S)-di-tert-butyl 2-(3-((S)-1-tert-butoxy-1-oxo-6-(3-(4-(trimethylstannyl)phenyl)ureido)hexan-2-yl)ureido)pentanedioate with 50 to 100 mCi of [ ]MIP-1095, respectively, in moderate radiochemical yields (50-70%) in as little as 10 min. The radioiododestannylation afforded the 123 I-labeled tri-tert-butyl esters that were purified using simple C18 Sep Pak columns and deprotected with trifluoroacetic acid to afford the desired radioiodinated inhibitors in >95% radiochemical purity. The specific activity was determined to be z4,000 mCi/Amol.
NAALADase inhibition by MIP-1072 and MIP-1095. The ability of nonradiolabeled MIP-1072 and MIP-1095 to inhibit the NAALADase activity of PSMA was tested in LNCaP cell lysates as previously described (19) with minor modifications. Briefly, LNCaP cells were collected, washed in 0.32 mol/L sucrose, and lysed in cold 50 mmol/L Tris-HCl (pH 7.4), 0.5% Triton X-100. The lysate was centrifuged at 20,000 Â g to remove insoluble material, then aliquoted and stored frozen at À80jC. LNCaP cell lysate (100 Ag) was added to 10 Amol/L 50 values using the Cheng-Prusoff equation (20) .
Cell culture. Human prostate cancer cell lines, LNCaP (PSMA positive) and PC3 (PSMA negative), were obtained from the American Type Culture Collection. PC3 cells transfected with either PSMA (PC3 PIP) or plasmid alone (PC3 flu) were obtained from Dr. Warren Heston (Cleveland Clinic, Cleveland, OH) and maintained as previously described (21 ]MIP-1095 for 0 to 2 h at 4jC and 37jC. At the indicated time, the media was removed and the cells were washed with a mild acid buffer [50 mmol/L glycine, 150 mmol/L NaCl (pH 3.0)] at 4jC for 5 min. Cells were then centrifuged at 20,000 Â g for 5 min. The supernatant (containing cell surface bound radioactivity) and the cell pellet (containing internalized radioactivity) were counted on a g-counter (22) .
Inoculation of mice with xenografts. All animal studies were approved by the Institutional Animal Care and Use Committee in accordance with the guidelines set forth by the USPHS Policy on Humane Care and Use of Laboratory Animals. Mice were housed under standard conditions in approved facilities with 12-h light/dark cycles and given food and water ad libitum. Male athymic NCr-nu/nu mice were purchased from Taconic. Mice were anesthetized by an i.p. injection of f0.5 mL/mouse avertin (19 mg/mL). For inoculation in mice, LNCaP or PC3 cells were resuspended at 10 7 cells/mL in a 1:1 mixture of cell culture medium/Matrigel (BD Biosciences). Each mouse was injected in the right flank with 0.25 mL of the cell suspension. Mice were used for tissue distribution studies when the tumors reached approximately 100 to 400 mm ]MIP-1095 at a specific activity of >1,000 mCi/Amol. Mice bearing LNCaP tumors were imaged 4 h postinjection and mice bearing PC-3 PIP or flu tumors were imaged at 2 h postinjection. A Gamma Medica X-SPECT scanner equipped with two opposing low-energy 0.5-mm aperture pinholes and tunable computed tomography (CT) was used for all scans. Mice were scanned over 180j in 5.5j, 45-s increments. A CT scan was performed before scintigraphy for both anatomic coregistration and attenuation correction. Data were reconstructed and fused using commercial software from Gamma Medica, which includes a 2D-OSEM algorithm. (18) . The structurally unrelated PSMA inhibitor, PMPA, was included as a positive control and displayed a K i of 2.1 F 0.1 nmol/L, in agreement with the K i determined by Tiffany and colleagues (23) .
[ (15, 26) despite the fact that immunohistochemistry and reverse transcription-PCR have shown PSMA to be expressed in the proximal tubules of kidney (9, 27) . This may be due to the fact that ProstaScint binds an internal epitope of PSMA (13, 14) , or, because of their size, antibodies do not penetrate tissues well and are not filtered by glomeruli. Despite the high accumulation in the LNCaP xenograft, the widespread use of ProstaScint as a diagnostic (Fig. 2, top) . Additionally, [ 123 I]MIP-1072 and [
123 I]MIP-1095 detected PC3 PIP (PSMA +) but not PC3 flu (PSMA À) tumors by SPECT/CTat 2 hours after injection (Fig. 2, bottom) , indicating that the uptake is specific to PSMA and is not related to blood flow or permeability differences between cell lines. As anticipated, high uptake was also observed in the kidneys, which express PSMA.
[ (Fig. 3) .
Discussion
We describe here the preclinical evaluation of two novel potential radiopharmaceuticals, were designed to target PSMA in prostate cancer cells and tissue. PSMA is expressed in normal prostate, brain, kidney proximal tubules, and intestinal brush border membranes. Importantly, expression is dramatically up-regulated in poorly differentiated, metastatic and hormone-refractory carcinomas (9) as well as after androgen deprivation therapy (28) and in lymph node metastases (29) . The function of PSMA in prostate cancer is unclear, although it is reported to play a role in tumor invasiveness (30) . It has been reported that increased expression of PSMA in primary prostate cancer correlates with other adverse traditional prognostic factors and independently predicts disease outcome (31, 32) . Numerous studies have shown its utility as a diagnostic marker and therapeutic target with a >90% prevalence in disease (9, 33) . Additionally, PSMA is expressed in the endothelial cells of tumor neovasculature of many solid tumors (21, 27) , indicating that it may have utility as a diagnostic or therapeutic molecular target in cancers other than prostate.
Several imaging modalities are currently being collectively used for the diagnosis, staging, and prognosis of prostate cancer metastases. Conventional cross-sectional imaging with CT and magnetic resonance imaging rely on anatomic changes (lesions, >1 cm) often resulting in missed lymph node metastases. Nodal enlargement due to metastases occurs relatively late in the progression of prostate cancer, and therefore, neither CT nor magnetic resonance imaging is effective at detecting the oftenmicroscopic lymph node metastases. Radionuclide bone scans are commonly used for monitoring bone metastases. However, false positives are common as a result of inflammation, previous bone injuries, and arthritis, and are especially problematic in older men (34) . Therefore the need exists for new methodologies of not only detecting the primary tumor, but metastatic lesions as well.
Molecular imaging, which relies on signal from a radiotracer that binds specifically to a biochemical marker on tumor cells rather than anatomic features, may provide a means to detect both primary cancer and metastases. SPECT and positron emission tomography are two methods commonly used to provide biochemical information through molecular imaging. 18 F-fluorodeoxyglucose is a glucose analogue that is readily taken up by hypermetabolic cancer cells and is an efficient means to detect many solid tumors (35) (36) (37) , but is not effective in most primary prostate tumors and metastases due to the low glycolytic rate of prostate cancer (38, 39) . Thus, we have undertaken an effort to improve the diagnosis and staging of prostate cancer by developing molecules that target a cancer-specific biochemical marker, PSMA, for imaging by conventional SPECT technology.
[ 123 I]MIP-1072 and [ 123 I]MIP-1095 were shown here to bind specifically and with high affinity to PSMA (+) LNCaP cells but not to PSMA (À) PC3 cells. Both compounds internalized in prostate cancer cells that express PSMA in a time-dependent, acidinsensitive manner. Because cellular internalization was shown at 37jC but not 4jC, it is believed that it occurs via the endocytotic pathway. Recently, other PSMA-specific inhibitors (40) and antibodies (12) have been reported to be internalized through endocytosis as well. The saturation binding and NAALADase inhibition studies revealed an f5-fold greater affinity of MIP-1095 over MIP-1072. This is likely a result of additional hydrophobic contacts outside of the PSMA binding pocket. The elucidation of the cocrystal structure of PSMA with both substrates and inhibitors revealed that electrostatic interactions between the carboxylic acids of the glutamic and aspartic acid residues and Arg 534/ Arg536, and Asn519 of PSMA are critical for binding (41) . In addition, there is a hydrophobic pocket accessory to the active site that may be exploited in the rational design of inhibitors. This information led us to design inhibitors based on a glutamate-urea-X heterodimer structural motif where X corresponds to an a amino acid. These molecules contain the three carboxylic acid groups required for binding to PSMA. The urea functional group interacts with the Zn 2+ containing active site and the side chains of Tyr552 and His553. Substantial differences in affinity have been reported for other halogenated glutamate-urea-lysine heterodimers of this series as a consequence of the nature of the halogen and position of the halogen on the aryl ring (18) . Several other glutamate-urea-X dimers with high affinity and selectivity for PSMA-expressing cells and xenografts have also been described (42) (43) (44) (45) (46) (47) (48) .
[ 123 I]MIP-1072 and [ 123 I]MIP-1095 exhibited peak LNCaP tumor uptake of 17.3 F 6.3 (at 1 hour) and 34.3 F 12.7 (at 4 hours) % ID/g, respectively. However, high uptake was also observed in the mouse kidneys, which could be blocked by the structurally unrelated PSMA inhibitor, PMPA, indicating that the uptake was mediated by specific binding to PSMA. Several reports have confirmed that PSMA is expressed in the mouse kidneys (25, 49) , and similar results have been shown with other agents targeting PSMA (43) (44) (45) (46) . Neither compound accumulated in the brain to an appreciable extent indicating that they do not cross the blood-brain barrier and are unlikely to interfere with the physiologic NAALADase activity of glutamatergic neurotransmission. In this regard, most imaging radiopharmaceuticals do not elicit pharmacologic responses as the actual mass of compound administered is typically at tracer levels. In addition, although PSMA is expressed in the human prostate and kidneys, a defined physiologic role has yet to be established so it is difficult to predict the effect that 123 I]MIP-1095 is cleared by both urinary and hepatobiliary routes. The differences in the clearance profiles do not seem to be related to metabolism as both compounds are stable in liver microsomes and blood plasma (data not shown). ProstaScint, like most antibodies, clears from the blood very slowly with peak accumulation in the LNCaP xenograft at the latest time point studied, resulting in a low tumor/background ratio and prolonged total body exposure to radiation. One other disadvantage of ProstaScint is that it targets the intracellular domain of PSMA (13, 14) , and because antibodies do not readily cross the cell membrane; it is thought that it binds only to necrotic cells of prostate tumors. More recently, however, anti-PSMA monoclonal antibodies that target an extracellular domain of PSMA, e.g., J591, have entered into clinical trials (50) . We have designed small molecules with affinities similar to that of ProstaScint and J591, but with enhanced ability to diffuse into the extravascular space and with faster blood clearance. 131 I is commonly used in the treatment of thyroid cancer as it emits high-energy (606 keV) h particles capable of ablating tumors. Of course, the potential for radiotherapy will depend upon the dose to nontarget tissues, in particular, the kidneys, which based on the data presented here are likely to be dose limiting. PSMA has been shown by immunohistologic techniques to be expressed in human kidneys (9, 27 123 I]MIP-1095, which may be capable of detecting both the primary prostate cancer as well as soft tissue and bone metastases, will not only satisfy this critical unmet need, but could alter the current paradigm for the detection and staging of prostate cancer and offer a unique opportunity to follow response to systemic therapies by noninvasive external imaging. Patient management would be significantly improved as these molecular imaging pharmaceuticals are designed to track specifically both the location and progression of prostate tumor metastases through their PSMA expression. 
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